Back

CRF Health

Software

Other

Realised

CRF Health

Realised Other Software

Verdane invested in CRF Health in 2013. At the time of investment, CRF was a top-three global provider of electronic patient reporting solutions. The company's strength on the global market made it well-positioned to capitalise on the strong market potential of the Clinical Outcome Assessment (COA) market. Conversion from paper to paperless trials meant the eCOA market was growing by an estimated 17-25% annually. Verdane gained majority control by buying out two minority shareholders and successfully developed CRF Health into the global leader in the electronic Clinical Outcome Assessment (eCOA) market, with a strong and resilient client base. The company was sold to Vitruvian Partners in 2015.

Changes implemented by Verdane included:
- an expanded product offering that fully captured the market shift from paper to paperless trials
- improvements in operational processes and governance structures
- cemented technology leadership in the eCOA market
- a broadened focus, including targeting new therapeutic areas and launching new, complementary services
- a strengthened board and management, as well as the implementation of company-wide employee incentive programme

Verdane invested in CRF Health in 2013. At the time of investment, CRF was a top-three global provider of electronic patient reporting solutions. The company's strength on the global market made it well-positioned to capitalise on the strong market potential of the Clinical Outcome Assessment (COA) market. Conversion from paper to paperless trials meant the eCOA market was growing by an estimated 17-25% annually. Verdane gained majority control by buying out two minority shareholders and successfully developed CRF Health into the global leader in the electronic Clinical Outcome Assessment (eCOA) market, with a strong and resilient client base. The company was sold to Vitruvian Partners in 2015.

Changes implemented by Verdane included:
- an expanded product offering that fully captured the market shift from paper to paperless trials
- improvements in operational processes and governance structures
- cemented technology leadership in the eCOA market
- a broadened focus, including targeting new therapeutic areas and launching new, complementary services
- a strengthened board and management, as well as the implementation of company-wide employee incentive programme